2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Sagar Lonial, MD, professor and chair, department of Hematology & Medical Oncology, Emory University School of Medicine, Chief Medical Officer, Winship Cancer Institute of Emory University, discusses treatment for smoldering multiple myeloma.
Sagar Lonial, MD, professor and chair, department of Hematology & Medical Oncology, Emory University School of Medicine, Chief Medical Officer, Winship Cancer Institute of Emory University, discusses treatment for smoldering multiple myeloma.
One of the biggest questions regarding smoldering multiple myeloma is whether or not patients with it require early treatment or simply observation. Lonial believes patients who are classified as having high-risk smoldering who need earlier treatment, should be reclassified as having standard multiple myeloma.
There may be non-high-risk patients that require treatment as well, says Lonial. There are small studies that are investigating this, but currently there is no evidence that patients with true smoldering should be treated earlier.
<<<
View more from the 2016 Congress on Hematologic Malignancies